RT Journal Article
SR Electronic
T1 Steroid Hormone Biosynthesis and Dietary Related Metabolites Associated with Excessive Daytime Sleepiness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.12.24313561
DO 10.1101/2024.09.12.24313561
A1 Faquih, Tariq
A1 Potts, Kaitlin
A1 Yu, Bing
A1 Kaplan, Robert
A1 Isasi, Carmen R
A1 Qi, Qibin
A1 Taylor, Kent D.
A1 Liu, Peter Y.
A1 Tracy, Russell P.
A1 Johnson, Craig
A1 Rich, Stephen S.
A1 Clish, Clary B.
A1 Gerzsten, Robert E.
A1 Rotter, Jerome I.
A1 Redline, Susan
A1 Sofer, Tamar
A1 Wang, Heming
YR 2024
UL http://medrxiv.org/content/early/2024/09/13/2024.09.12.24313561.abstract
AB Background Excessive daytime sleepiness (EDS) is a complex sleep problem that affects approximately 33% of the United States population. Although EDS usually occurs in conjunction with insufficient sleep, and other sleep and circadian disorders, recent studies have shown unique genetic markers and metabolic pathways underlying EDS. Here, we aimed to further elucidate the biological profile of EDS using large scale single- and pathway-level metabolomics analyses.Methods Metabolomics data were available for 877 metabolites in 6,071 individuals from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and EDS was assessed using the Epworth Sleepiness Scale (ESS) questionnaire. We performed linear regression for each metabolite on continuous ESS, adjusting for demographic, lifestyle, and physiological confounders, and in sex specific groups. Subsequently, gaussian graphical modelling was performed coupled with pathway and enrichment analyses to generate a holistic interactive network of the metabolomic profile of EDS associations.Findings We identified seven metabolites belonging to steroids, sphingomyelin, and long chain fatty acids sub-pathways in the primary model associated with EDS, and an additional three metabolites in the male-specific analysis. The identified metabolites particularly played a role in steroid hormone biosynthesis.Interpretation Our findings indicate that an EDS metabolomic profile is characterized by endogenous and dietary metabolites within the steroid hormone biosynthesis pathway, with some pathways that differ by sex. Our findings identify potential pathways to target for addressing the causes or consequences of EDS and related sleep disorders.Funding Details regarding funding supporting this work and all studies involved are provided in the acknowledgments section.Evidence before this study There is a growing recognition of the paramount importance of sleep on health and cardiometabolic disease. Excessive daytime sleepiness (EDS), one of the key common sleep treatment targets, has been linked to increased risk of mortality, hypertension, cardiovascular disease, car accidents as well as decrease in life quality, and productivity. Despite its impact on health, much remains unknown about the biological mechanisms of EDS and if those mechanisms are independent from other sleep disorders. Recent genetic evidence that shows that EDS is associated with specific genetic biomarkers supports the need to further study the underlying biology of EDS.Added value of this study Here, we used measurements of metabolites, the products and by-products of metabolism to identify the metabolomic profile of EDS. Metabolites are produced by the biological reactions within the body via proteins—themselves products of genes—and by the breakdown of external sources such as nutritional intake and breathing air pollutants. Therefore, metabolomics enables study of the effects of nutrition, environmental exposures, and genetics. In this study we aimed to identify the metabolites that were associated with excessive daytime sleepiness. Additionally, we mapped these metabolites into a publicly available online biological network of human metabolism pathways to obtain an understanding of our findings on a larger scale.Implications of all the available evidence Identifying the metabolites and pathways related to daytime sleepiness provides insights into the biological mechanisms of EDS and suggests future research opportunities to identify targets for prevention, prediction, and treatments for EDS and potentially other sleep disorders coupled with sleepiness. In this study we found 7 such metabolites—some endogenously synthesised and some obtained from dietary sources—associated with EDS. The network analysis implicated the steroid hormone biosynthesis pathway as a shared pathway underlying those metabolites, and identified linkages to key metabolites related to sleep: melatonin and cortisol metabolism.Competing Interest StatementDr. Redline discloses consulting relationships with Eli Lilly Inc, Jazz Pharma, and Apnimed Inc. Additionally, Dr. Redline serves as an unpaid board member for the Alliance for Sleep Apnoea Partners and has received loaned equipment for a multi-site study: oxygen concentrators from Philips Respironics and polysomnography equipment from Nox Medical.Funding StatementThis work was supported by the National Institute of Health (NIH) grants R01HL153814 (to H.W.), R01HL161012 (to T.S.). Support for metabolomics data was graciously provided by the JLH Foundation (Houston, Texas). The Hispanic Community Health Study/Study of Latinos was carried out as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State University (N01-HC65237). The following Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer of funds to the NHLBI: National Center on Minority Health and Health Disparities, the National Institute of Deafness and Other Communications Disorders, the National Institute of Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, and the Office of Dietary Supplements. The authors thank the staff and participants of HCHS/SOL for their contributions. The MESA projects are conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420, UL1TR001881, DK063491, and R01HL105756. A full list of participating MESA investigators and institutes can be found at http://www.mesa-nhlbi.org. The authors thank the other investigators, the staff, and the participants of the MESA study for their contributions. Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Metabolomics for "NHLBI TOPMed: "Multi-Ethnic Study of Atherosclerosis (MESA)" (phs001416) was performed at Broad Institute and Beth Israel Metabolomics Platform (HHSN268201600034I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. Phase 1 TOPMed metabQTL results were generated in a collaboration between the TOPMed Metabolomics Working Group, the TOPMed Informatics Research Center, and the TOPMed parent studies contributing metabolite data and distributed to TOPMed investigators.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Institutional Review Board of Brigham and Women's Hospital. HCHS/SOL assessments were approved by the Institutional Review Boards of the participating institutions. This study was approved by the institutional review boards of all MESA field centres. All participants provided written informed consent in both studies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesHCHS/SOL study and MESA pseudonymized data are available via controlled-access application to dbGaP (study accession phs000810 and phs003288.v1.p1) or via approved data use agreement with the Data Coordinating Centre of the HCHS/SOL (University of North Carolina) and MESA (University of Washington). For more details see https://sites.cscc.unc.edu/hchs and https://internal.mesa-nhlbi.org/. Individual WGS data for TOPMed and metabolomic data for MESA can be obtained by application to dbGaP with accession number phs001416.v2.p1. https://sites.cscc.unc.edu/hchs https://internal.mesa-nhlbi.org/ https://www.ncbi.nlm.nih.gov/gap/